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Abstract
Aims—Secondhand smoke (SHS) exposure is associated with elevated CHD risks. Yet the
pathways through which this may operate have not been investigated in epidemiologic studies
with objective SHS exposure measures and a wide range of CHD risk factors associated with
active smoking. Therefore we investigate associations between SHS exposure and CHD risk
factors, to clarify how SHS exposure may raise risk of CHD.
Methods—Cross-sectional population-based study of 5029 men and women aged 59–80 years
from primary care practices in Great Britain. Smoking, behavioural and demographic information
was reported in questionnaires; nurses made physical measurements and took blood samples for
analysis of serum cotinine and markers of inflammation, hemostasis and endothelial dysfunction.
Results—Active cigarette smokers had lower albumin and higher triglycerides, CRP, IL-6, white
cell count, fibrinogen, blood viscosity, factor VIII, VWF and t-PA than non-smokers. Among non-
smokers, serum cotinine levels were independently positively associated with CRP, fibrinogen,
factor VIII, VWF and t-PA and inversely associated with albumin, after adjustment for age,
gender, social and behavioural factors. The differences in CRP, fibrinogen and albumin between
cotinine ≤0.05 and >0.7 ng/ml were one-third to one half the size of differences between cotinine
≤0.05 ng/ml and current smokers, but were of similar magnitude for VWF and t-PA.
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Conclusions—Endothelial, inflammatory and haemostatic markers related to CHD risk showed
independent associations with SHS exposure in the same direction as those for active smoking.
Results aid understanding of the associations between SHS exposure and elevated CHD risks.
Abbreviations
SHS, secondhand smoke; MI, myocardial infarction; CVD, cardiovascular disease; CHD,
coronary heart disease; CI, confidence interval; HDLc, high density lipoprotein cholesterol; CRP,
C-reactive protein; IL-6, interleukin-6; IL-18, interleukin-18; VWF, vonWillebrand factor; TNFα,
tumor necrosis factor-alpha; MMP-9, matrix metalloproteinase-9; BMI, body mass index; BP,
blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; t-PA, tissue
plasminogen activator; LR, likelihood ratio
Keywords
Secondhand smoke; CVD risk factors; Inflammation; Epidemiology
1 Introduction
Secondhand smoke (SHS) is associated with elevated risks of coronary heart disease (CHD)
[1–3] and stroke [4]. Epidemiologic studies based on self-reported exposure to SHS have
reported a 1.2- to 1.3-fold increase in risk of CHD, independent of established CHD risk
factors [2,3]; whilst a study using serum cotinine as a marker of overall SHS exposure
reported slightly higher hazard ratios, around 1.4 [5]. In both types of study, the risks
associated with high SHS exposure were very similar to risks from light active smoking,
despite the much greater exposure to tobacco smoke in active smoking [1,5,6]. However, the
mechanisms by which SHS elevates CHD risk remain uncertain. Several possible pathways
are indicated by experimental studies in adults; acute SHS exposure has been shown to
increase platelet activity [7,8], lower HDL-cholesterol (HDLc) levels [9], elevate
homocysteine levels [10], or increase circulating levels of inflammatory and hemostatic
markers which are themselves associated with CHD risk, such as white cell count [11].
Experimental data also suggest that SHS may cause endothelial damage, increasing
endothelial cell turnover [7] and causing a similar degree of endothelial dysfunction to that
observed in active smokers [12]. Active cigarette smoking influences all these pathways
[13–16].
Whilst most evidence about how SHS affects cardiovascular risk factors comes from short-
term laboratory studies [3], evidence about the relation of SHS exposure to the risk
pathways at the population level is limited. Most epidemiologic studies of SHS exposure
and CHD risk factors rely on self-report [17]. To date cotinine, a quantitative marker of
recent tobacco exposure [18], has been used to measure SHS exposure in relation to CHD
risk factors in only two population-based studies, the British Regional Heart Study and the
third National Health and Nutrition Examination Survey (NHANES III) [5,19,20].
Population studies indicate that SHS exposure (either self-report or cotinine level) is
associated with significantly higher systolic and diastolic blood pressure (SBP and DBP),
BMI [5,20] and homocysteine levels [17,19], although associations with lipids [19–21],
white blood cell count, C-reactive protein (CRP) and fibrinogen [17,19,22] are less
consistent.
In order to examine potential pathways linking SHS exposure to CHD risk, we examine the
epidemiological associations between SHS exposure, assessed by serum cotinine, with a
wide range of activation markers of inflammation and hemostasis that existing data suggest
could be part of the response to SHS exposure and are implicated in CHD risk in older men
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and women. Analyses examine the effect of adjustment for important confounders and set
the associations between SHS exposure and risk factors in the context of associations
observed in active smokers. We exclude from analyses ex-smokers who quit recently (to
avoid carry over effects), participants taking warfarin (which would affect levels of
coagulation factors) and participants with a history of MI, diabetes or stroke, to avoid
reverse causality.
2 Methods
2.1 Study design
Two parallel prospective studies of 60–79 year olds: 4252 men surveyed in 1998–2000 and
4286 women surveyed in 1999–2001. Participants were from a single General Practice in 24
British towns, 77% response rate (men) [23] and 60% (women) [24]. Near identical
protocols for data collection were used. Participants completed detailed questionnaires
including health behaviour data. Nurses made physical measurements and collected fasting
venous blood samples (see supplementary data). All participants provided written informed
consent to the investigation and ethical approval was provided by all relevant local Research
Ethics Committees.
2.2 Laboratory assays
Liquid chromatography tandem mass spectrometry was used to assay cotinine in serum
samples of non-smokers, the unit of quantification was 0.1 ng/mL and the lower limit of
detection was 0.02 ng/mL. Cotinine values at the limit of quantification (0.1) were assigned
a value of 0.05 ng/ml. Further details, including assays for blood lipids and metabolic
markers, inflammatory and hemostatic markers are described in supplementary data.
2.3 Classification of smokers and non-smokers
Non-smokers reported no current cigarette, cigar or pipe smoking or any smoking in the past
5 years, and had serum cotinine ≤15 ng/mL, consistent with other literature [25]. 99% of
self-reported non-smokers with cotinine data had levels <15 ng/mL, 76 non-smokers with
cotinine >15 ng/mL were recoded as smokers of 1–9 cigarettes/day. No participants reported
taking nicotine replacement therapy (British National Formulary code 4.10) [26].
2.4 Statistical methods
Serum cotinine was highly positively skewed and therefore analyzed as categories, the
highest exposure group was chosen because cotinine >0.7 ng/mL is reportedly associated
with elevated CHD risks [5], the lowest group had undetectable exposure and participants
with intermediate exposure were split into two equal groups. Cotinine was also natural log
transformed to base 2 to display the effect of doubling in cotinine level. Means or
proportions of behavioural and demographic factors selected a priori were calculated for
groups of non-smokers (defined by cotinine level) and active smokers (defined by cigarettes/
day). P values for linear trends in cotinine levels in non-smokers were obtained using linear
or logistic regression analyses of each of the behavioural or demographic variables, with
log2[cotinine] as a predictor, adjusted for age, gender and region of residence. CVD markers
were examined: skewed variables were natural log-transformed and adjusted for time of
measurement if they showed significant diurnal variation. BP, BMI and waist circumference
were also adjusted for intra-observer variation. No diurnal or seasonal (October–March vs
April–September) variation in cotinine levels was observed. The percentage change between
the mean CVD marker levels for non-smokers in the lowest compared with highest cotinine
categories were calculated as [(mean ≤0.05 ng/mL) − (mean 0.71–15 ng/mL)/mean
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≤0.05 ng/mL]. Percentage differences were also calculated comparing non-smokers with
≤0.05 ng/mL cotinine to smokers (1–9 cigarettes/day).
Linear regression models were used to estimate the linear associations between each
inflammatory, endothelial or hemostatic marker (response variable) and log2[cotinine], so
the beta coefficients represent the risk factor difference associated with a doubling in
cotinine concentration. Models were first adjusted for age, gender and region of residence,
and next for physical inactivity, light alcohol drinking, smoking history (time since quitting
smoking or never-smoking) and social class as categorical variables and BMI as a
continuous variable. Interaction terms between BMI and gender were fitted for the
inflammatory markers where interactions were evident (likelihood ratio (LR) test P < 0.05).
Finally, adjustments were made for HDLc, triglycerides and SBP as continuous variables.
Further, logistic regression models contrasted cotinine ≤0.05 with >0.7 ng/mL, because
cotinine >0.7 ng/mL was reportedly associated with elevated CHD risks [5]. Age and gender
were examined as modifiers of the cotinine-CVD marker associations. Interactions were
tested using LR tests. As sensitivity analyses, models were restricted to (i) never-smokers
and (ii) participants with cotinine ≤9.5 ng/mL.
3 Results
Among 8152 participants (4267 women, 4245 men) with questionnaire data on cigarette
smoking, 90% (n = 7375) had cotinine assays. The analysis sample excluded (i) n = 251
(3%) ex-smokers who quit <5 years previously, (ii) 162 taking warfarin (iii) 1472 with a
history (self-report or record in GP notes) of MI, diabetes or stroke, (iv) 733 active cigarette
smokers. The analysis sample comprised 4757 non-smokers (of which 52% never smoked).
For comparison, descriptive analyses included 272 smokers of 1–9 cigarettes/day. Of 4757
non-smokers, 38% had undetectable cotinine (≤0.05 ng/mL) and the remainder were divided
into three groups (Table 1).
The characteristics of active smokers and non-smokers with different levels of SHS
exposure are shown in Table 1. Geometric mean cotinine was much higher in smokers than
non-smokers; 100.58 ng/mL vs 0.15 ng/mL, P < 0.001. Active smokers tended to be from
manual social groups, resident in the north of the UK, and physically inactive. Non-smokers
with higher compared with lower serum cotinine levels (greater SHS exposure), were also
from manual social class groups, resident in the north of the UK, physically inactive and
were younger, male, ex-smokers rather than never-smokers.
Table 2 presents adjusted mean values of CVD risk markers for active smokers and non-
smokers with different levels of SHS exposure, compared to the non-smokers with cotinine
≤0.05 ng/mL. Active smokers had lower BMI, fasting insulin and albumin compared with
non-smokers with cotinine ≤0.05 ng/mL. Smokers had higher triglycerides, CRP, IL-6,
white blood cell count, fibrin D-dimer, plasma and blood viscosity, fibrinogen, VWF, t-PA,
platelet count, homocysteine, CD40 Ligand and MMP-9. The largest percentage differences
in CVD risk factor between smokers and non-smokers with cotinine ≤0.05 ng/mL were for
CRP (62%), IL-6 (41%), MMP-9 (27%) fibrin D-dimer (21%) and white blood cell count
(18%). Active smoking was not appreciably associated with blood pressure, waist
circumference, total and HDL cholesterol, glucose, mean platelet volume, factor VII, factor
VIII, haematocrit, IL-18 or TNFα levels.
Among non-smokers, higher cotinine levels were associated with higher BMI, waist
circumference, fasting insulin, CRP, IL-6, blood and plasma viscosity, fibrinogen, factor
VIII, VWF, t-PA and with lower albumin (Table 2, Fig. 1a–d). Modest associations with
factor VII, triglycerides and platelet count did not reach conventional levels (5%) of
statistical significance; there were no associations with BP, fasting lipids and glucose, white
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cell count, fibrin D-dimer, mean platelet volume, haematocrit, homocysteine, IL-18, CD40L,
MMP-9 and TNFα. Among non-smokers the largest percentage changes in CVD risk factors
in participants with cotinine >0.7 ng/mL compared with ≤0.05 ng/mL were for CRP (26%),
IL-6 (12%) and t-PA (9%).
Table 3 presents associations in non-smokers between log2[cotinine] and each risk factor in
models adjusted first for gender, age and region of residence, then additionally for social and
behavioural confounders including smoking history and BMI. The coefficients represent the
risk factor difference associated with a doubling in cotinine concentration. Among factors
where associations with increasing SHS exposure were in the same direction as associations
with active smoking in earlier analyses, on full adjustment, CRP, IL6, fibrinogen, factor
VIII, VWF, t-PA and albumin were still associated with cotinine, although adjustments
attenuated the strengths of associations by up to half (for CRP, IL-6 and t-PA) and up to a
quarter (albumin and factor VIII). Adjusted associations between cotinine level and blood
and plasma viscosity were attenuated to the null. Cotinine levels were not consistently
associated with BP, lipids, insulin or glucose, white cell count, fibrin D-dimer, mean platelet
volume, platelet count, haematocrit, homocysteine, IL-18, CD40 ligand, MMP-9 or TNFα,
after adjustment for health behaviours, social class and BMI. Additional adjustments for
lipids and BP did not materially affect results except for IL-6, which was attenuated to the
null. Treating cotinine as a dichotomous variable, (>0.7 ng/ml compared to ≤0.05) yielded
similar results.
Restricting analyses in Table 3 to never-smokers (n = 2496) reduced precision; associations
of cotinine with BMI, CRP, IL-6 and albumin were of similar magnitude to those reported
above for all current non-smokers but confidence intervals were wide and included the null
value. Associations with waist circumference and fibrinogen were not found in never-
smokers. Other significant associations between cotinine and risk markers were not
materially changed by restriction to never-smokers, or to non-smokers with cotinine
≤9.5 ng/mL. Variables which were robustly associated with cotinine (Table 3), showed
similar associations in both sexes and did not vary by age in regression models with cotinine
as a continuous or a dichotomous variable (all LR tests of interactions, P > 0.05). Sensitivity
analyses using 0.025 and 0.075 rather than 0.05 ng/ml for undetectable cotinine gave a
similar pattern of results.
4 Discussion
Several cardiovascular risk factors showed independent associations with SHS exposure in
the same direction as active smoking, adjusted for age, gender, social and behavioural
factors. These included CRP, fibrinogen, factor VIII, VWF and t-PA (all of which had
higher circulating levels both with active smoking and SHS exposure). Although active
smokers had higher triglyceride and insulin levels and lower mean BMI and waist
circumference than non-smokers with low SHS exposure, these factors did not show similar
patterns of associations with SHS exposure in adjusted analyses.
4.1 Strengths and weaknesses
This is the first study to examine associations between serum cotinine levels in non-smokers
and an exceptionally wide range of established and novel CVD risk factors and benefits
from a large population including both sexes sets results in context using active smokers.
Serum cotinine is an objective marker that is well validated to measure overall SHS
exposure, which has advantages over self-reported exposure [18]. This study is unique in
investigating a far wider range of risk factors than the two earlier studies with cotinine data
[5,19]. A limitation is the inability to completely exclude residual confounding of
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associations between cotinine and CVD markers, particularly by socio-economic factors and
adiposity.
4.2 Other studies
Our data comparing risk factor levels between active smokers and non-smokers with
undetectable cotinine are potentially less biased than those of other studies, which generally
included participants exposed to SHS in the non-smoker reference group. However, overall
the results are similar in showing that active smokers had lower BMI and waist
circumference and albumin compared with non-smokers, but higher triglycerides [13–16],
inflammatory, hemostatic and endothelial markers [13,27,28]. Our results for SHS exposure,
finding associations with biomarkers of inflammation, hemostasis and endothelial
dysfunction rather than with established CHD risk factors are consistent with an earlier
report relating self-reported SHS exposure of >1 h/week to higher CRP and white blood cell
count, but not to BP or lipids [29], although other studies do report that SHS exposure is
associated with lower HDLc [3]. Our findings indicating a generalised inflammatory
response to SHS exposure fit with prior evidence that CRP is raised (with self-report or
cotinine) [17,30], although we did not observe elevated white blood cell counts reported
elsewhere [17,19,29]. The observed associations between hemostatic factors (several of
which are also acute phase reactants) and SHS exposure are consistent with some earlier
data. Positive associations between SHS exposure (self-reported or cotinine levels) and
fibrinogen levels have been reported previously [19,22]. Although associations between
active smoking and higher VWF levels have been reported previously [14,15], our study
appears to be the first reporting associations with SHS exposure. The association with VWF
fits with reports of impaired flow-mediated dilatation, a more direct measure of endothelial
dysfunction, in smokers than non-smokers and an inverse dose-response association of
poorer dilatation with greater SHS exposure [12]. Active smoking is associated with
elevated oxidative stress which may in turn alter endothelial function, for instance through
reduced nitric oxide (NO) bioavailability, although data were not available here to
investigate these pathways for SHS exposure. We did not replicate positive associations
between SHS exposure (self-reported or cotinine) and homocysteine [10,17,19], possibly
because we had fewer participants with homocysteine data.
4.3 Interpretation of results
SHS exposure exhibited graded trends with several, although not all inflammatory,
hemostatic and endothelial markers which are also related to active smoking. Selection bias
in unlikely given our reasonably high response rates, as is misclassification of active
smokers wrongly placed into high SHS group; participants with elevated cotinine (>15 ng/
ml) were excluded from SHS analyses. Results are not affected by using a more
conservative cotinine threshold for active smoking (9.5 ng/ml) [31]. Restricting analyses to
self-reported never-smokers reduced power and adjusted associations with BMI, CRP, IL-6,
albumin and fibrinogen were no-longer significant, bringing into question their causative
roles. Residual confounding, particularly by social factors is possible despite statistically
controlling for social class. We specifically examined the effect of adjustment for social
class after adjusting for behavioural and demographic factors and social class little affected
the cotinine coefficient. Observed associations between SHS and endothelial, inflammatory
and hemostatic markers were somewhat attenuated by adjustments, although CRP, VWF,
tPA, fibrinogen and albumin remained statistically significant after adjustment for social,
behavioural and established risk factors plus BMI. It is biologically plausible that
associations between SHS exposure and CVD risk markers are causal. The cardiovascular
system is very sensitive to SHS and inflammation and platelet activation are prominent in
the response to SHS; fibrinogen, VWF and t-PA are markers of both processes [3,19]. As in
previous studies [19], the influence of SHS on inflammatory and hemostatic markers starts
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at very low levels of exposure (being apparent well below 0.7 ng/ml, the cotinine level
associated with increased CHD risk in our earlier study [5]) and are disproportionate to
exposure levels. The magnitude of differences in CRP, fibrinogen and albumin between high
and low SHS exposure are around one-third to one half of the magnitude of differences
between active smokers and low SHS exposure, although the differences are of similar
magnitude for VWF and t-PA. Given current evidence about the strengths of association of
CRP, VWF and t-PA to CHD risk [28,32,33], the potential impact of SHS exposure
(cotinine ≤0.05 vs >0.7) acting through each pathway is approximately 5–10% and could
therefore be expected to affect population levels of CHD. Several of the inflammatory and
hemostatic factors have been implicated in causation of type 2 diabetes [34] which would be
consistent with an earlier report implicating SHS exposure in type 2 diabetes [35].
5 Conclusions
This study suggests that SHS exposure, even at very low levels has important influences on
endothelial, inflammatory and hemostatic factors. The findings emphasize the continued
importance of efforts to reduce exposure to SHS, even at very low levels.
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Fig. 1.
Associations between serum cotinine level in non-smokers, or active smokers of 1–9
cigarettes/day and (a) CRP (b) VWF (c) t-PA (d) Albumin.
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Table 1
Association between serum cotinine in non and active smokers and demographic or behavioural factors [mean
or %]a.
Non-smokers (serum cotinine ng/mL) Cigarette smokers P (trend) b P (no difference)b
N ≤0.05 0.06–0.19 0.20–0.70 0.71–15 (1–9/day) In non-smokers ≤0.05 ng/mL vs smokers
(n = 1994) (n = 1130) (n = 1034) (n = 599) (n = 272)
Age (years) 5029 69.3 68.4 68.0 67.9 69.1 <0.001 0.470
Women (%) 5029 62.5 55.0 48.7 44.4 59.9 <0.001 0.310
Northern region of
residence (%)
5029 33.2 39.5 40.8 46.1 41.9 <0.001 <0.001
Manual
occupational class
(%)
4735 41.2 44.9 56.3 65.7 56.3 <0.001 <0.001
Light alcohol
consumption (1–15
units/week)
4499 39.5 43.8 45.2 39.4 39.8 0.777 0.868
Quit smoking >20
years ago (%)
4757 27.2 26.1 28.6 29.6 – 0.770 –
Never smokers (%) 4757 57.2 55.2 47.7 39.7 – <0.001 –
Low physical
activity (<3 h
moderate/
vigorous/week)
4848 62.1 59.6 59.8 60.9 73.4 0.008 <0.001
a
Sample excludes participants (i) with prevalent diabetes, stroke or MI, (ii) taking warfarin and (iii) ex-smokers who quit <5 years ago.
b
P-value from regression model of each factor with log2[cotinine], adjusted for age, gender and region.
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Table 2
Association between serum cotinine in non-smokers and active smokers with cardiovascular risk factorsa.
Non-smokers (serum cotinine ng/mL) Cigarette smokers P (trend)e P (no difference)f
N ≤0.05 0.06–0.19 0.20–0.70 0.71–15 (1–9/day) In non-smokers ≤0.05 ng/mL vs smokers
(n = 1994) (n = 1130) (n = 1034) (n = 599) (n = 272)
Blood pressure
 Systolic (mm/Hg)b,c 5000 148.82 147.74 147.31 150.08 146.23 0.774 0.070
 Diastolic (mm/Hg)b,c 5000 82.92 82.40 82.73 83.90 81.60 0.305 0.059
Lipids
 Total cholesterol (mMol/L) 5001 6.39 6.37 6.35 6.37 6.37 0.976 0.743
 HDL cholesterol (mMol/L) 4989 1.53 1.51 1.52 1.53 1.49 0.193 0.112
 Triglyceride (mMol/L)c,d 4868 1.56 1.57 1.55 1.60 1.68 0.089 0.008
Metabolic markers
 Body mass index (Kg/m2) 4488 26.70 27.11 27.34 27.37 25.62 <0.001 <0.001
 Waist circumference (cm) 4394 90.22 91.35 91.58 92.06 89.10 <0.001 0.160
 Insulin (μu/L)c,d 4891 6.91 7.04 6.94 7.35 6.29 0.028 0.009
 Glucose (mMol/L)c,d 4850 5.66 5.63 5.64 5.63 5.59 0.833 0.095
Inflammatory/hemostatic markers
 C-reactive protein (mg/L)d 4961 1.41 1.49 1.60 1.78 2.29 <0.001 <0.001
 IL-6 (pg/mL)d 4994 2.16 2.19 2.28 2.41 3.05 <0.001 <0.001
 White cell count (^109/
L)c,d
4793 6.60 6.61 6.60 6.66 7.76 0.175 <0.001
 Albumin (g/L)c 4868 44.33 44.20 44.08 43.87 43.59 <0.001 <0.001
 Fibrin D-dimer (ng/mL)d 5012 83.18 83.73 84.96 80.60 100.30 0.846 0.001
 Plasma viscosity (mPa s)c 4720 1.28 1.29 1.28 1.29 1.30 0.009 0.006
 Blood viscosity (mPa s)c,d 4624 1.55 1.56 1.56 1.57 1.58 0.007 0.006
 Fibrinogen (g/L)c 4875 3.19 3.18 3.22 3.28 3.49 0.026 <0.001
 Factor VII (IU/dL)c 4868 133.51 132.89 133.07 135.82 136.00 0.052 0.172
 Factor VIII (IU/dL) 5011 141.72 144.08 145.09 148.83 144.63 <0.001 0.173
 Von Willebrand factor (IU/
dL)
5014 137.20 140.39 142.85 144.05 146.86 <0.001 <0.001
 t-PA (ng/mL)c 4880 9.26 9.43 9.70 10.04 10.05 <0.001 0.001
 Mean platelet volume (fL) 4852 8.74 8.72 8.73 8.76 8.61 0.497 0.269
 Hematocrit (%) 4921 45.25 45.19 45.12 44.90 45.43 0.193 0.332
 Platelet count (^109/L) 4921 246.67 245.94 248.39 251.35 262.83 0.065 <0.001
Published as: Atherosclerosis. 2010 February ; 208(2): 550–556.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Jefferis et al. Page 13
Non-smokers (serum cotinine ng/mL) Cigarette smokers P (trend)e P (no difference)f
N ≤0.05 0.06–0.19 0.20–0.70 0.71–15 (1–9/day) In non-smokers ≤0.05 ng/mL vs smokers
(n = 1994) (n = 1130) (n = 1034) (n = 599) (n = 272)
 Homocysteine (μmol/L) 2224 12.87 13.00 12.72 13.49 14.43 0.100 0.013
 IL-18 (pg/mL)d 1607 369.13 365.01 385.78 380.73 389.93 0.196 0.287
 CD40 Ligand (pg/mL)d 1614 5.42 5.23 5.32 5.61 6.09 0.318 0.029
 MMP-9 (ng/mL)d 1614 448.93 483.14 452.90 474.47 571.03 0.219 <0.001
 TNFα (pg/mL)d 1595 1.73 1.84 1.77 1.82 1.91 0.426 0.116
a
Sample excludes participants (i) with pre-existing diabetes, stroke or MI, (ii) taking warfarin and (iii) ex-smokers who quit <5 years ago. Means
are adjusted for age, gender and region of residence
b
Adjusted for intra-observer variation
c
Adjusted for time of day
d
Geometric mean
e
P-value for trend from linear regression models in non-smokers of each marker with log2[cotinine] adjusted for age, gender and region.
f
P-value for difference between cotinine ≤0.05 ng/mL and smokers (≥1cigarette/day), from logistic regression models of each marker adjusted for
age, gender and region.
Published as: Atherosclerosis. 2010 February ; 208(2): 550–556.
Sponsored D
ocum
ent 
Sponsored D
ocum
ent 
Sponsored D
ocum
ent
Jefferis et al. Page 14
Table 3
Association between cardiovascular risk factors and serum cotinine in non-smokers. The figures represent the
risk factor difference associated with a doubling in cotinine concentration.
N Model 1 = age + region + gender Model 2 = Model 1 + health behaviours + SEP + BMIa
Blood pressure
 Systolic (mm/Hg)b,c 4273 −0.04 (−0.46, 0.36) −0.27 (−0.69, 0.15)
 Diastolic (mm/Hg)b,c 4273 0.06 (−0.14, 0.26) −0.02 (−0.23, 0.18)
Lipids
 Total cholesterol (mMol/L) 4277 −0.00 (−0.02, 0.02) −0.00 (−0.02, 0.02)
 HDL cholesterol (mMol/L) 4266 −0.00 (−0.01, 0.00) −0.00 (−0.01, 0.01)
 Triglyceride (mMol/L)c,d 4176 0.00 (−0.00, 0.01) −0.00 (−0.01, 0.01)
Metabolic Markers
 Body mass index (Kg/m2) 4295 0.16 (0.09, 0.23) 0.11 (0.04, 0.19)
 Waist circumference (cm) 4203 0.44 (0.25, 0.63) 0.27 (0.08, 0.46)
 Insulin (μu/L)c,d 4192 0.01 (−0.00, 0.02) 0.00 (−0.01, 0.01)
 Glucose (mMol/L)c,d 4162 0.002 (−0.004, 0.000) −0.002 (−0.005, 0.000)
Inflammatory/hemostatic markers
 C-reactive protein (mg/L)d 4241 0.05 (0.03, 0.07) 0.03 (0.01, 0.05)
 IL-6 (pg/mL)d 4267 0.03 (0.02, 0.04) 0.01 (0.00, 0.02)
 White cell count (^109/L)c,d 4116 0.00 (−0.00, 0.01) 0.00 (−0.00, 0.01)
 Albumin (g/L)c 4176 −0.09 (−0.14,−0.05) −0.07 (−0.12, −0.03)
 Fibrin D-dimer (ng/mL)d 4282 0.00 (−0.01, 0.01) −0.01 (−0.02, 0.01)
 Plasma viscosity (mPa s)c 4053 0.002 (0.001, 0.004) 0.001 (−0.000, 0.003)
 Blood viscosity (mPa s)c,d 3978 0.003 (0.001, 0.004) 0.002 (−0.000, 0.003)
 Fibrinogen (g/L)c 4176 0.02 (0.00, 0.03) 0.02 (0.00, 0.03)
 Factor VII (IU/dL)c 4170 0.44 (−0.08, 0.96) 0.06 (−0.47, 0.59)
 Factor VIII (IU/dL) 4279 1.41 (0.81, 2.00) 1.09 (0.48, 1.69)
 Von Willebrand Factor (IU/dL) 4283 1.98 (1.20, 2.76) 1.75 (0.95, 2.54)
 t-PA (ng/mL)c 4182 0.17 (0.11, 0.24) 0.08 (0.02, 0.15)
 Mean platelet volume (fL) 4147 0.01(−0.02, 0.04) 0.00 (−0.03, 0.03)
 Hematocrit (%) 4212 −0.05 (−0.11, 0.01) −0.06 (−0.12, −0.00)
 Platelet count (^109/L) 4212 1.10 (−0.02, 2.24) 0.93 (−0.20, 2.10)
 Homocysteine(μmol/L)(men only) 2024 0.11 (−0.03, 0.24) 0.06 (−0.08, 0.20)
 IL-18 (pg/mL)d 1349 0.01 (−0.01, 0.02) 0.01 (−0.01, 0.02)
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N Model 1 = age + region + gender Model 2 = Model 1 + health behaviours + SEP + BMIa
 CD40 Ligand (pg/mL)d 1355 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
 MMP-9 (ng/mL)d 1355 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
 TNFα (pg/mL)d 1340 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
Results in bold reach conventional statistical significance levels (5%).
a
Adjusted for alcohol intake (six categories), smoking history (five categories), physical activity (inactive/active), SEP(manual, non-manual, armed
forces), BMI (and BMI*gender where appropriate). Waist circumference not adjusted for BMI.
b
Adjusted for intra-observer variation.
c
Adjusted for time of day.
d
Natural log transformed: coefficient reported for log variable represents a proportional change.
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